Proteintech Deal Bolsters Multiomics But Doesn't Fix Core Growth Concerns

What happened

10x Genomics stock rose on news of its acquisition of Proteintech Genomics, adding high-plex proteomics tools to its single-cell and spatial platforms. The deal strengthens the company's multiomics capabilities and may improve platform stickiness, but it does not address the core revenue challenges of flat product sales and declining instrument revenue. Recent filings show that reported revenue growth in 2025 was driven entirely by non-recurring IP settlements, not organic demand. Management guides flat-to-low-single-digit growth into 2026, with NIH funding risk impacting ~20-25% of revenue. The acquisition is strategically sound but the stock's risk/reward remains unfavorable at current levels given the underlying business pressures.

Implication

The Proteintech acquisition adds valuable multiomics capabilities but does not alter the fundamental investment thesis. Core products and services revenue is flat-to-declining, with growth reliant on non-recurring IP settlements. NIH funding risk persists, and spatial consumables alone cannot offset weaknesses in Chromium and instruments. The stock's rally has been driven by sentiment and IP cash, not operational improvement. Investors should maintain caution and wait for evidence of organic acceleration ex-IP before adding exposure.

Thesis delta

The acquisition is strategically positive but incremental; it does not change the outlook for organic revenue growth or profitability. The thesis remains a potential sell, with the stock near the bull case value of $22 offering limited upside and significant downside risk to $14-16. The key variable remains whether spatial consumables can sustain high-teens growth while Chromium stabilizes, which the deal does not directly impact.